1. Scrip
  2. >>Therapy Areas

Teva begins US shipments of generic Effexor XR per 2006 settlement

 
• By Nancy Faigen

Teva Pharmaceutical Industries began shipments of a generic version of Pfizer's extended-release venlafaxine product, Effexor XR capsules, on 1 July, for the treatment of major depressive disorder, following final approval of its ANDA from the US FDA in late June. The brand product has annual US sales of about $2.7 billion based on IMS sales data.

Teva Pharmaceutical Industries began shipments of a generic version of Pfizer's extended-release venlafaxine product, Effexor XR capsules, on 1 July, for the treatment of major depressive disorder, following final approval of its ANDA from the US FDA in late June. The brand product has annual US sales of about $2.7 billion based on IMS sales data.

Shipments of the product had been expected as per a 2006 settlement and licence agreement with Wyeth, now a unit...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

More from Therapeutic Category

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

BioNTech To Buy mRNA Rivals CureVac

 
• By Andrew McConaghie

The $1.25bn buyout is a simple deal for BioNTech, bringing new mRNA R&D and manufacturing capacity while also ending a bothersome patent dispute.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?